Maria Gonzalez-Nunez

Maria Gonzalez-Nunez

Auto-generated profile, based on publicly available information

Maria Gonzalez-Nunez

Center for Biochemical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2021 in Circulation Research
Verified
Journal Article
Closed access
PDF file
DKDuco Steven Koenis
Duco Steven Koenis
IBIssa Beegun
Issa Beegun
CJCharlotte Camille Jouvene
Charlotte Camille Jouvene
GAGabriel Amador Aguirre
Gabriel Amador Aguirre
PSPatricia Regina Souza
Patricia Regina Souza
Jesmond DalliJesmond Dalli
Jesmond Dalli
Rationale: Resolution mechanisms are central in both the maintenance of homeostasis and the return to catabasis following tissue injury and infections. Among the proresolving mediators, the essential fatty acid-derived specialized proresolving lipid mediators (SPM) govern immune responses to limit disease severity. Notably, little is known about the relationship between the expression and activity of SPM pathways, circulating phagocyte function and disease severity in patients infected with the novel severe acute respiratory syndrome coronavirus 2 leading to coronavirus disease 2019 (COVID-19). Objective: Herein, we investigated the link between circulating SPM concentrations and phagocyte activation status and function in patients with COVID-19 (n=39) compared with healthy (n=12) and post-COVID-19 (n=8) volunteers. Methods and Results: Lipid mediator profiling demonstrated that plasma SPM concentrations were upregulated in patients with mild COVID-19 and are downregulated in those with severe disease. SPM concentrations were correlated with both circulating phagocyte activation status and function. Perturbations in plasma SPM concentrations and phagocyte activation were retained after the resolution of COVID-19 clinical symptoms. Treatment of patients with dexamethasone upregulated both the expression of SPM biosynthetic enzymes in circulating phagocytes and plasma concentration of these mediators. Notably, incubation of phagocytes from patients with COVID-19 with SPM rectified their phenotype and function. This included a downregulation in the expression of activation markers, a decrease in the tissue factor and inflammatory cytokine expression, and an upregulation of bacterial phagocytosis. Conclusions: The present findings suggest that downregulation of systemic SPM concentrations is linked with both increased disease severity and dysregulated phagocyte function. They also identify the upregulation of these mediators by dexamethasone as a potential host protective mechanism elicited by this drug in patients with COVID-19. Taken together, our findings elucidate a role for altered resolution mechanisms in the disruption of phagocyte responses and the propagation of systemic inflammation in COVID-19.

4 February 2022 in Science Advances
Verified
Journal Article
Open access
RMRoberta De Matteis
Roberta De Matteis
MFMagdalena B. Flak
Magdalena B. Flak
MGMaria Gonzalez-Nunez
Maria Gonzalez-Nunez
SAShani Austin-Williams
Shani Austin-Williams
FPFrancesco Palmas
Francesco Palmas
Jesmond DalliJesmond Dalli
Jesmond Dalli
Inflammation is linked with carcinogenesis in many types of cancer including colorectal cancer (CRC). Aspirin is recommended for the prevention of CRC, although the mechanism(s) mediating its immunomodulatory actions remain incompletely understood. Here, we demonstrate that aspirin increased concentrations of the immune-regulatory aspirin-triggered specialized proresolving mediators (AT-SPMs), including AT-lipoxin A 4 and AT-resolvin D1, in colonic tissues during inflammation-associated CRC (I-CRC). Aspirin also down-regulated the expression of the checkpoint protein programmed cell death protein-1 in macrophages and CD8 + T cells from the colonic mucosa. Inhibition of AT-SPM biosynthesis or knockout of the AT-SPM receptor Alx/Fpr2 reversed the immunomodulatory actions of aspirin on macrophages and CD8 + T cells and abrogated its protective effects during I-CRC. Furthermore, treatment of mice with AT-SPM recapitulated the immune-directed actions of aspirin during I-CRC. Together, these findings elucidate a central role for AT-SPM in mediating the immune-directed actions of aspirin in regulating I-CRC progression.

16 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
MNMaria Gonzalez Nuñez
Maria Gonzalez Nuñez
LVLuiz Ricardo da Costa Vasconcellos
Luiz Ricardo da Costa Vasconcellos
JMJose Garrido Mesa
Jose Garrido Mesa
Rafael Cardoso Maciel Costa SilvaRafael Cardoso Maciel Costa Silva
Rafael Cardoso Maciel Costa Silva
AHAbderrahman Hachani
Abderrahman Hachani
EAEzra Aksoy
Ezra Aksoy
Phosphoinositide 3-kinase delta (PI3Kδ) is essential for immune cell functions, preventing immunodeficiency and inflammation; however, its role in dendritic cell (DC)-mediated immune regulation remains unknown. Here, we report a key role for DC-intrinsic PI3Kδ in linking microbial recognition with antigen presentation for effective T-cell priming. Using genetic and functional assays, we demonstrate that PI3Kδ deficiency in DCs leads to broad dysregulation of intestinal CD4⁺ T-cell immunity, characterized by impaired regulatory T-cell expansion and increased susceptibility to colitis. DC-based studies show that PI3Kδ links pattern-recognition-receptor signaling to MHC class I- and II-restricted presentation of phagosome-associated antigens by facilitating NOX2-dependent oxidative burst through RAC2, while mitigating inflammasome activation. In contrast, PI3Kδ deficiency disrupts phagosomal pH balance, leading to accelerated acidification and proteolysis of antigens, impairing T-cell activation. Our study identifies PI3Kδ as a key coordinator of phagosome dynamics, important for DC adaptive programming that shapes T-cell responses and supports intestinal immune homeostasis.